|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008838,
umls-concept:C0016360,
umls-concept:C0024501,
umls-concept:C0045093,
umls-concept:C0205179,
umls-concept:C0205263,
umls-concept:C0205267,
umls-concept:C0282461,
umls-concept:C0332283,
umls-concept:C0443196,
umls-concept:C0854776,
umls-concept:C1274040,
umls-concept:C1517927,
umls-concept:C2603343
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2008-8-25
|
|
pubmed:abstractText |
The role of chemoradiation with systemic chemotherapy compared with chemotherapy alone in locally advanced pancreatic cancer (LAPC) is uncertain.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1569-8041
|
|
pubmed:author |
pubmed-author:AparicioTT,
pubmed-author:AzzedineAA,
pubmed-author:BedenneLL,
pubmed-author:BonnetainFF,
pubmed-author:BossetJ FJF,
pubmed-author:BouchéOO,
pubmed-author:ButelJJ,
pubmed-author:ChauffertBB,
pubmed-author:HammenRR,
pubmed-author:MaingonPP,
pubmed-author:MariettiGG,
pubmed-author:MineurLL,
pubmed-author:MornexFF,
pubmed-author:RougierPP,
pubmed-author:StremsdoerferNN
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
19
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1592-9
|
|
pubmed:meshHeading |
pubmed-meshheading:18467316-Adult,
pubmed-meshheading:18467316-Aged,
pubmed-meshheading:18467316-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18467316-Biopsy, Needle,
pubmed-meshheading:18467316-Chemotherapy, Adjuvant,
pubmed-meshheading:18467316-Cisplatin,
pubmed-meshheading:18467316-Combined Modality Therapy,
pubmed-meshheading:18467316-Deoxycytidine,
pubmed-meshheading:18467316-Dose-Response Relationship, Drug,
pubmed-meshheading:18467316-Drug Administration Schedule,
pubmed-meshheading:18467316-Female,
pubmed-meshheading:18467316-Fluorouracil,
pubmed-meshheading:18467316-Follow-Up Studies,
pubmed-meshheading:18467316-Humans,
pubmed-meshheading:18467316-Immunohistochemistry,
pubmed-meshheading:18467316-Infusions, Intravenous,
pubmed-meshheading:18467316-Male,
pubmed-meshheading:18467316-Middle Aged,
pubmed-meshheading:18467316-Neoplasm Invasiveness,
pubmed-meshheading:18467316-Neoplasm Staging,
pubmed-meshheading:18467316-Pancreatic Neoplasms,
pubmed-meshheading:18467316-Probability,
pubmed-meshheading:18467316-Radiotherapy, Adjuvant,
pubmed-meshheading:18467316-Radiotherapy Dosage,
pubmed-meshheading:18467316-Remission Induction,
pubmed-meshheading:18467316-Risk Assessment,
pubmed-meshheading:18467316-Survival Analysis,
pubmed-meshheading:18467316-Treatment Outcome
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study.
|
|
pubmed:affiliation |
Department of Oncology, Anticancer Center G.F. Leclerc, Dijon, France.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase III
|
